therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG-0403) Y. Nagata * , M. Hiraoka # , T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura Radiation Therapy Study Group of Japan Clinical Oncology Group *Study Coordinator, # Primary Investigator ASTRO, Boston, Oct. 28-31, 2012.
5
Embed
Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer.
First report for inoperable population of a phase II trial by Japan Clinical Oncology Group
(JCOG-0403)Y. Nagata*, M. Hiraoka#, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura
Radiation Therapy Study Group of Japan Clinical Oncology Group*Study Coordinator, #Primary Investigator
ASTRO, Boston, Oct. 28-31, 2012.
• Stereotactic body radiation therapy (SBRT) delivers very targeted beams of radiation to a small area over a few days
• SBRT is less invasive than surgery• SBRT is considered to work against T1N0M0 lung
cancers• First report for operable population was presented
in ASTRO 2010.• This presentation is the first
report for inoperable population.
• First clinical trial to study SBRT for both inoperable & operable stage IA lung cancers
• From 2004 to 2008, 104 patients from 15 institutions with early-stage inoperable non-small cell lung cancer were studied
• Patients underwent 4 times daily radiotherapy over the course of four to eight days
• Each treatment is non-invasive and painless, much like receiving an X-ray
• Patients followed for almost three years (37 months) after treatment
• Overall survival rate for patients three years after SBRT was 60 percent
• Patients reported only mild side effects from the treatment
• Patients with inoperable early lung cancer should consider this treatment